Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL

Michael Northend(Royal London Hospital), William Townsend(University College Hospital), David Wrench(St Bartholomew's Hospital), Elizabeth Davies(Manchester Royal Infirmary), Richard Karim(Dorset County Hospital), Claire Roddie(Cancer Institute (WIA)), Pam McKay(Beatson West of Scotland Cancer Centre), William Wilson(Cancer Research UK), Elizabeth H. Phillips(University of Manchester), Juanah Addada(Royal Derby Hospital), Indrani Karpha(Clatterbridge Cancer Centre NHS Foundation Trust), Anna Cowley(East Sussex Healthcare NHS Trust), Christopher Williams(Northumbria Healthcare NHS Foundation Trust), Joel Cunningham(James Paget University Hospital), Anita Arasaretnam(Royal Sussex County Hospital), Andrea Kühnl(King's College Hospital), Rocío Figueroa Mora(Nottingham University Hospitals NHS Trust), Wendy Osborne(Newcastle upon Tyne Hospitals NHS Foundation Trust), Andrew Davies(University Hospital Southampton NHS Foundation Trust), Sarah Challenor(Royal Cornwall Hospital), Tobias Menne(Newcastle upon Tyne Hospitals NHS Foundation Trust), Dima El‐Sharkawi(Royal Marsden Hospital), Christopher P. Fox(University of Nottingham), Vikram Singh(University of Liverpool), Cathy Burton(Leeds Teaching Hospitals NHS Trust), Ying Ying Peng(St George's Hospital), Iman Qureshi(University Hospitals Birmingham NHS Foundation Trust), Shalal Sadullah(James Paget University Hospital), Neil Phillips(University Hospitals of North Midlands NHS Trust), Angus Broom(Western General Hospital), Rebecca Auer(St Bartholomew's Hospital), Hau Wui Sim(Northwick Park Hospital), Nimish Shah(National Health Service)
Blood Advances
January 12, 2022
Cited by 44


Related Papers